Trial Profile
Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 26 Oct 2017 Results published in the Blood
- 29 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 29 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.